Calidi Biotherapeutics Company Top Insiders
| CLDI Stock | 1.38 0.06 4.17% |
Calidi Biotherapeutics employs about 28 people. The company is managed by 11 executives with a total tenure of roughly 66 years, averaging almost 6.0 years of service per executive, having 2.55 employees per reported executive. Assessment of Calidi Biotherapeutics' management performance can provide insight into the firm performance.
Calidi Biotherapeutics Management Team Effectiveness
The company has return on total asset (ROA) of (1.5823) % which means that it has lost $1.5823 on every $100 spent on assets. This is way below average. Calidi Biotherapeutics' management efficiency ratios could be used to measure how well Calidi Biotherapeutics manages its routine affairs as well as how well it operates its assets and liabilities. The current Return On Tangible Assets is estimated to decrease to -1.64. The Calidi Biotherapeutics' current Return On Capital Employed is estimated to increase to -4.41. As of now, Calidi Biotherapeutics' Total Assets are increasing as compared to previous years. The Calidi Biotherapeutics' current Total Current Assets is estimated to increase to about 10.7 M, while Net Tangible Assets are projected to decrease to (47.7 M).The current Common Stock Shares Outstanding is estimated to decrease to about 655 K. The current Net Loss is estimated to decrease to about (24 M)
Calidi Biotherapeutics Workforce Comparison
Calidi Biotherapeutics is number one stock in number of employees category among its peers. The total workforce of Health Care industry is currently estimated at about 86.0. Calidi Biotherapeutics totals roughly 28.0 in number of employees claiming about 33% of equities under Health Care industry.
Calidi Biotherapeutics Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Calidi Biotherapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Calidi Biotherapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Calidi Biotherapeutics insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Leftwich Scott over a month ago Acquisition by Leftwich Scott of 11684 shares of Calidi Biotherapeutics subject to Rule 16b-3 | ||
Andrew Jackson over two months ago Acquisition by Andrew Jackson of 30000 shares of Calidi Biotherapeutics at 1.58 subject to Rule 16b-3 | ||
Stewart Alan R. over three months ago Acquisition by Stewart Alan R. of 20217 shares of Calidi Biotherapeutics at 1.09 subject to Rule 16b-3 | ||
Stewart Alan R. over six months ago Acquisition by Stewart Alan R. of 25995 shares of Calidi Biotherapeutics subject to Rule 16b-3 | ||
Leftwich Scott over six months ago Acquisition by Leftwich Scott of 11684 shares of Calidi Biotherapeutics subject to Rule 16b-3 | ||
Allan Camaisa over six months ago Disposition of 10000 shares by Allan Camaisa of Calidi Biotherapeutics at 1.62 subject to Rule 16b-3 | ||
Allan Camaisa over a year ago Acquisition by Allan Camaisa of 70155 shares of Calidi Biotherapeutics at 1.15 subject to Rule 16b-3 | ||
Peoples George over a year ago Insider Trading |
Calidi Biotherapeutics Notable Stakeholders
A Calidi Biotherapeutics stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Calidi Biotherapeutics often face trade-offs trying to please all of them. Calidi Biotherapeutics' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Calidi Biotherapeutics' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Eric Poma | CEO Director | Profile | |
| Allan Camaisa | Chairman CEO | Profile | |
| Boris MD | President Officer | Profile | |
| Andrew Jackson | Chief Officer | Profile | |
| PharmD Santidrian | Head Officer | Profile | |
| Stephen Thesing | Chief Officer | Profile | |
| Thomas Herrmann | Managing Development | Profile | |
| Wendy Esq | Chief Officer | Profile | |
| Amish Patel | Senior Operations | Profile | |
| David MBA | Chief Development | Profile | |
| Guy MD | Consultant Officer | Profile |
About Calidi Biotherapeutics Management Performance
The success or failure of an entity such as Calidi Biotherapeutics often depends on how effective the management is. Calidi Biotherapeutics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Calidi management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Calidi management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (1.56) | (1.64) | |
| Return On Capital Employed | (4.65) | (4.41) | |
| Return On Assets | (1.56) | (1.64) | |
| Return On Equity | (14.43) | (13.71) |
Calidi Biotherapeutics Workforce Analysis
Traditionally, organizations such as Calidi Biotherapeutics use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Calidi Biotherapeutics within its industry.Calidi Biotherapeutics Manpower Efficiency
Return on Calidi Biotherapeutics Manpower
| Revenue Per Employee | 0.0 | |
| Revenue Per Executive | 0.0 | |
| Net Loss Per Employee | 793.2K | |
| Net Loss Per Executive | 2M | |
| Working Capital Per Employee | 26.1K | |
| Working Capital Per Executive | 66.5K |
Complementary Tools for Calidi Stock analysis
When running Calidi Biotherapeutics' price analysis, check to measure Calidi Biotherapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Calidi Biotherapeutics is operating at the current time. Most of Calidi Biotherapeutics' value examination focuses on studying past and present price action to predict the probability of Calidi Biotherapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Calidi Biotherapeutics' price. Additionally, you may evaluate how the addition of Calidi Biotherapeutics to your portfolios can decrease your overall portfolio volatility.
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Commodity Directory Find actively traded commodities issued by global exchanges |